QUANTITATIVE DETECTION OF CYTOMEGALOVIRUS BY USING A COM

巨细胞病毒(CMV)对接受异基因骨髓移植的患者可能是毁灭性的。在这些患者中，快速检测CMV感染可以挽救生命，使及时给予抗CMV药物。临床上还需要对临床标本中存在的巨细胞病毒进行定量测量，以监测治疗和预测出现耐药变异。一家商业供应商开发了一种研究分析方法，允许使用定量聚合酶链式反应(PCR)来测量从全血中提取的CMV DNA。我们正在使用美国医学实验室收集的外周血白细胞对这种PCR方法进行评估，并将其结果与CMV抗原血症定量分析(在美国医学实验室进行)的结果进行比较，该方法检测多形核白细胞和单核细胞中是否存在CMV pp65早期结构蛋白。结果不一致的样本将被送往微生物参考实验室进行第二次聚合酶链式反应检测。到目前为止的结果表明，商品化的聚合酶链式反应至少与巨细胞病毒抗原血症检测一样敏感。需要对更多的样本进行测试，才能进行统计上有效的比较。这个项目已经停止。

Cytomegalovirus (CMV) can be devastating in the patient who has undergone an allogenic bone marrow transplant. Rapid detection of CMV infection in these patients can be lifesaving, allowing the prompt administration of anti-CMV drugs. There is also a clinical need for a quantitative measure of the CMV present in the clinical specimen to allow for monitoring therapy and predicting emergence of drug-resistant variants. A research assay has been developed by a commercial vendor that allows the use of quantitative polymerase chain reaction (PCR) to measure the CMV DNA extracted from whole blood. We are evaluating this PCR assay using peripheral blood leukocytes collected by American Medical Laboratories and comparing the results with those of the CMV antigenemia quantitative assay (performed at American Medical Laboratories) that detects the presence of CMV pp65 early structural protein in polymorphonuclear leukocytes and monocytes. Specimens with discrepant results will be sent to Microbiology Reference Laboratories to be evaluated using a second PCR assay. Results thus far indicate that the commercial PCR is at least as sensitive as the CMV antigenemia assay. More specimens need to be tested for a statistically valid comparison to be made.This project has been discontinued.